C07D 471/16
Peri-condensed systems
C07D471/16 (Peri-condensed systems) appears on 273 US grants and 368 published applications in this corpus.
Search patents in C07D- Granted patents
- 273
- Published applications
- 368
- Assignees
- 171
- Inventors
- 1,017
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 5 | 5 |
| 2003 | 3 | 2 |
| 2004 | 4 | 9 |
| 2005 | 2 | 1 |
| 2006 | 1 | 2 |
| 2007 | 3 | 5 |
| 2008 | 3 | 7 |
| 2009 | 2 | 7 |
| 2010 | 3 | 14 |
| 2011 | 2 | 8 |
| 2012 | 7 | 7 |
| 2013 | 9 | 16 |
| 2014 | 8 | 17 |
| 2015 | 12 | 21 |
| 2016 | 19 | 17 |
| 2017 | 17 | 21 |
| 2018 | 17 | 10 |
| 2019 | 16 | 27 |
| 2020 | 12 | 28 |
| 2021 | 16 | 25 |
| 2022 | 18 | 28 |
| 2023 | 13 | 25 |
| 2024 | 13 | 20 |
| 2025 | 26 | 26 |
| 2026 | 11 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tricyclic derivatives and related uses1 Sep 2026US 12,723,045 B2MOMA Therapeutics, Inc.
- Organic compounds21 Jul 2026US 12,685,731 B2Intra-Cellular Therapies, Inc.
- Indolo[3.2.1-jk]carbazole-6-carbonitrile derivatives as blue fluorescent emitters for use in OLEDS21 Jul 2026US 12,690,385 B2
- Tricyclic kinase inhibitors and uses thereof26 May 2026US 12,637,463 B2Dana-Farber Cancer Institute, Inc.
- High-activity Wnt pathway inhibitor compound12 May 2026US 12,622,917 B2Adlai Nortye Biopharma Co., Ltd.
- Organic compounds8 Oct 2026US 2026/0306489 A1Intra-Cellular Therapies, Inc.
- Heterocyclic compounds as parp1 inhibitors1 Oct 2026US 2026/0297102 A1Synnovation Therapeutics, Inc.
- Novel methods10 Sep 2026US 2026/0265253 A1Intra-Cellular Therapies, Inc.
- Fused ring piperidine compound, and preparation method therefor and use thereof6 Aug 2026US 2026/0224590 A1Center for Excellence In Molecular Cell Science, Chinese Academy of Sciences
- Substituted benzene compound6 Aug 2026US 2026/0226065 A1Daiichi Sankyo Company, Limited
Most cited
By later US patents
- Substituted pyridoindoles as serotonin agonists and antagonists112US 6,699,852 B2Bristol-Myers Squibb Pharma Company · 2004
- 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals108US 8,648,077 B2Intra-Cellular Therapies, Inc. · 2014
- Substituted heterocycle fused gamma-carbolines105US 7,071,186 B2Bristol-Myers Squibb Pharma Company · 2006
- Substituted pyridoindoles as serotonin agonists and antagonists103US 6,849,619 B2Bristol-Myers Squibb Company · 2005
- Substituted heterocycle fused γ-carbolines103US 7,183,282 B2Bristol-Myers Squibb Pharma Company · 2007